NIOX Group PLC

82C

Company Profile

  • Business description

    NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).

  • Contact

    1 Robert Robinson Avenue
    The Magdalen Centre
    The Oxford Science Park
    OxfordOX4 4GA
    GBR

    T: +44 3303309356

    E: [email protected]

    https://www.niox.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    97

Stocks News & Analysis

stocks

Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?

All that glitters is not gold.
stocks

Chart of the Week: Looking past the oil shock to find consumer opportunities

Shoppers are being hit by double whammy of oil and rising rates.
stocks

ASX data center player sells US assets to bolster balance sheet

Asset sale in response to growing investor concerns.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,107.0036.900.41%
CAC 408,241.3158.11-0.70%
DAX 4024,751.17167.52-0.67%
Dow JONES (US)49,779.20131.39-0.26%
FTSE 10010,301.59137.07-1.31%
HKSE26,626.28412.501.57%
NASDAQ25,974.54135.590.52%
Nikkei 22562,833.843,320.725.58%
NZX 50 Index13,270.61125.420.95%
S&P 5007,371.406.280.09%
S&P/ASX 2008,878.1032.700.37%
SSE Composite Index4,180.0919.920.48%

Market Movers